bioAffinity Technologies, Inc. (BIAF)vsThermo Fisher Scientific Inc (TMO)
BIAF
bioAffinity Technologies, Inc.
$7.95
-15.34%
HEALTHCARE · Cap: $4.78M
TMO
Thermo Fisher Scientific Inc
$609.82
+1.10%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 785123% more annual revenue ($46.34B vs $5.90M). TMO leads profitability with a 15.0% profit margin vs -257.3%. TMO earns a higher WallStSmart Score of 60/100 (C+).
BIAF
Avoid34
out of 100
Grade: F
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIAF.
Margin of Safety
-76.7%
Fair Value
$345.06
Current Price
$609.82
$264.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
19.0% revenue growth
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -433.7% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BIAF
The strongest argument for BIAF centers on Price/Book, Revenue Growth. Revenue growth of 19.0% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : BIAF
The primary concerns for BIAF are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BIAF profiles as a growth stock while TMO is a value play — different risk/reward profiles.
TMO carries more volatility with a beta of 0.85 — expect wider price swings.
BIAF is growing revenue faster at 19.0% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 34/100) and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
bioAffinity Technologies, Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
Visit Website →Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?